Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
Kyverna Therapeutics appointed Ritesh Srivastava as Chief Legal and Compliance Officer to strengthen leadership as it prepares for the commercialization of its lead asset, miv-cel. Mr. Srivastava joins from BPGbio and previously served as Global Compliance Officer at Spectrum Pharmaceuticals, bringing extensive experience in corporate governance and regulatory compliance. In connection with his appointment, Mr.
Key figures
- Drug Name
- miv-cel (mivocabtagene autoleucel, KYV-101)
- Vesting term years
- 4
- Option grant shares
- 260000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.